1. Draw 0.5 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl or roll until completely dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe.

GHRP-2 is a synthetic growth hormone secretagogue that binds to and activates ghrelin (GH secretagogue) receptors. This activation triggers potent, pulsatile release of growth hormone from the pituitary gland in a dose-dependent manner. Clinical studies in GH-deficient children demonstrated meaningful GH increases even at low doses (0.3 to 3.0 mcg/kg), with escalating doses over several months showing sustained efficacy. In healthy adults, doses of 100 mcg SC daily produce acute GH stimulation, while routine protocols typically maintain 100 to 300 mcg/day to balance efficacy with receptor sensitivity. The peptide has been well tolerated in clinical trials with no significant adverse effects or toxicity reported at these dosage range

• Stimulates robust pulsatile GH release that may support favorable body composition changes and
  metabolic effects.
• In combination therapies (e.g., with GHRH analogs), can significantly increase IGF-1 levels when
  administered with perfect compliance.
• Generally well tolerated with placebo-like safety profile; transient side effects may include mild hunger
  sensation or flushing.
• Long-term therapy (8 to 24 months in GH-deficient subjects) has maintained positive effects on growth velocity with careful monitoring.

Occasional mild injection-site reactions (redness, irritation) may occur with subcutaneous administration.